The heterogenous CXCR4 expression shown in these studies shows that CXCR4-targeted imaging cannot replace 18F-FDG in lung cancer; however, CXCR4-targeted imaging with 68Ga-Pentixafor can be used to select patients who may benefit from these therapies and to monitor treatment response. This evidence concerns the gene CXCR4 and lung carcinoma.